Cinobufacini Tablets Combined With Chemotherapeutic Protocol in Treatment of Diffuse Large B Cell Lymphoma

• Status: Recruiting
• Trial end date: 2021-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Diffuse large B cell lymphoma (DLBCL), as the most common subtype non-Hodgkin lymphoma (NHL), has great heterogeneity in clinical manifestations, histological morphology and prognosis. R-CHOP Protocol (Rituximab + Vindesine + Cyclophosphamide + Epirubicin + Prednisone) is the gold therapeutic criteria for patients with NHL, and it is also used as the first-line treatment for patients with DLBCL. After treatment, 50％～60％of patients with DLBCL receive complete remission (CR), 30％～40％ recurrent and 10% will never be cured due to initial and secondary drug tolerance. This study aimed to explore whether Cinobufacini Tablets had synergistic effect in the treatment of DLBCL, and whether its action was in close association with the positive expression of Na+/K+-ATPase α3, and to observe the rates of adverse reactions induced by Cinobufacini Tablets during treatment.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Xinjiang Medical University
• Treatments: Bufanolides; Buformin; Cyclophosphamide; Doxorubicin; Epirubicin; Prednisone; Rituximab; Vincristine; Vindesine

Criteria

For control and trial groups A:

Inclusion Criteria:

• Patients aged 18-70 years old;

• Patients with eastern Collaborative Oncology Group (ECOG) performance status (PS) score: 0～3 points;

• International prognostic index (IPI): ≤3 points;

• Patients who were diagnosed as diffuse large B cell lymphoma (DLBCL) with initial treatment by histopathology;

• Patients with more than 1 measurable nidus (common CT or MRI scanning diameter ≥ 20 mm, and spiral CT scanning diameter ≥ 10 mm);

• Patients without dysfunction of important organs, and had normal blood routine, hepatorenal function and cardiac function. White blood cell count (WBC) ≥4.0×109/L, neutrophil count ≥1.5×109/L; platelet (PLT) count ≥100×109/L; hemoglobin (HGB) ≥95g/L; serum bilirubin (Bil) ≤1.5 folds of the upper limit of normal value, alanine transaminase (ALT) and aspartate aminotransferase (AST) ≤2 folds of the upper limit of normal value, and serum creatinine (Scr) ≤1.5mg/dl;

• Patients with expected survival time>3 months;

• Patients who were well informed of this study and signed the informed consent forms.

• Patients who received administration of Rituximab.

Exclusion Criteria:

• Patients who did not conform to above criteria;

• Patients who were receiving other anti-cancer therapies;

• Patients with DLBCL affected by primary breast gland, lung, testis, bone, peri-orbit, peri-spine, central nerve system and bone marrow;

• Patients with double expression, double strike, trinary expression and trinary strike and CD5+;

• Patients complicated with other non-DLBCL primary malignant tumors;

• Patients who had poor compliance with their families;

• Patients with one of the following conditions: uncontrolled metastatic nidi of central nerve system, dysfunction of important organs and severe cardiac diseases like congestive heart failure, uncontrollable arrhythmia, angina pectoris that needed long-term drug administration, valvular heart diseases, myocardial infarction and refractory hypertension, pregnancy or lactation, chronic infectious wounds, and history of uncontrollable psychological diseases.

• Patients had previous history of treatment with Cinobufacini Tablets.

For control and trial groups B

Inclusion Criteria:

• Patients aged 18-70 years old;

• Patients with eastern Collaborative Oncology Group (ECOG) performance status (PS) score: 0～3 points;

• International prognostic index (IPI): ≤3 points;

• Patients who were diagnosed as diffuse large B cell lymphoma (DLBCL) with initial treatment by histopathology;

• Patients with more than 1 measurable nidus (common CT or MRI scanning diameter ≥ 20 mm, and spiral CT scanning diameter ≥ 10 mm);

• Patients without dysfunction of important organs, and had normal blood routine, hepatorenal function and cardiac function. White blood cell count (WBC) ≥4.0×109/L, neutrophil count ≥1.5×109/L; platelet (PLT) count ≥100×109/L; hemoglobin (HGB) ≥95g/L; serum bilirubin (Bil) ≤1.5 folds of the upper limit of normal value, alanine transaminase (ALT) and aspartate aminotransferase (AST) ≤2 folds of the upper limit of normal value, and serum creatinine (Scr) ≤1.5mg/dl;

• Patients with expected survival time>3 months;

• Patients who were well informed of this study and signed the informed consent forms.

• Patients who did not receive administration of Rituximab.

Exclusion Criteria:

• Patients who did not conform to above criteria;

• Patients who were receiving other anti-cancer therapies;

• Patients with DLBCL affected by primary breast gland, lung, testis, bone, peri-orbit, peri-spine, central nerve system and bone marrow;

• Patients with double expression, double strike, trinary expression and trinary strike and CD5+;

• Patients complicated with other non-DLBCL primary malignant tumors;

• Patients who had poor compliance with their families;

• Patients with one of the following conditions: uncontrolled metastatic nidi of central nerve system, dysfunction of important organs and severe cardiac diseases like congestive heart failure, uncontrollable arrhythmia, angina pectoris that needed long-term drug administration, valvular heart diseases, myocardial infarction and refractory hypertension, pregnancy or lactation, chronic infectious wounds, and history of uncontrollable psychological diseases.

• Patients had previous history of treatment with Cinobufacini Tablets.